https://www.selleckchem.com/pr....oducts/bi-1015550.ht
90; 95% CI, 0.65-1.24; = 0.64), crude prevalence (OR, 1.82; 95% CI, 0.23-14.19; = 0.57), adjusted prevalence (OR, 1.22; 95% CI, 0.50-2.96; = 0.66), IOP change during ICS treatment (mean difference [MD] +0.01 mmHg; 95% CI, -0.19-0.20; = 0.95), and single measurement IOP (MD +0.37 mmHg; 95% CI, -0.24-0.97; = 0.23). Time-to-event analysis for glaucoma development as one of the secondary endpoints (adjusted hazard ratio, 0.52; 95% CI, 0.28-0.96) suggested a reverse association between ICS and glaucoma. The ophthalmological side effects o
Like
Comment
Share
